Insider · CIK 0001853327
Scott L Burrows
cfoofficer
Files at SYRE (Spyre Therapeutics, Inc.). First filing Sep 3, 2025, latest Oct 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $4.8M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SYRE: Spyre Therapeutics, Inc.
SYREOct 9, 2026 · close 85.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Spyre Therapeutics, Inc. | $2.3M 25,000 shares | -26% | +460% from low-18% from high | |
| 32Weak | Spyre Therapeutics, Inc. | $2.3M 25,732 shares | -24% | +497% from low-19% from high | |
| 41Moderate | SYREsell Spyre Therapeutics, Inc. | $300k 18,428 shares | -16% | +41% from low-58% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +17,500 | $14.50 | $254k | 97,262 | 10 d ago |
| Sep 30, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -17,500 | $89.89 | $1.6M | 79,762 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +7,500 | $14.50 | $109k | 87,262 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -600 | $89.07 | $53k | 86,662 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $90.27 | $135k | 85,162 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,100 | $91.92 | $193k | 83,062 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,071 | $92.95 | $285k | 79,991 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -229 | $93.57 | $21k | 79,762 | 10 d ago |
| Sep 30, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 319,857 | 10 d ago |
| Oct 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 312,357 | 10 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +7,500 | $14.50 | $109k | 105,494 | 39 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -900 | $86.25 | $78k | 104,594 | 39 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -4,384 | $87.11 | $382k | 100,210 | 39 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -2,016 | $88.03 | $177k | 98,194 | 39 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -200 | $89.04 | $18k | 97,994 | 39 d ago |
| Sep 2, 2026 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -18,232 | $89.35 | $1.6M | 79,762 | 39 d ago |
| Sep 1, 2026 | SYRE Spyre Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 337,357 | 39 d ago |
| Sep 2, 2025 | SYRE Spyre Therapeutics, Inc. | SOpen-market sale Common Stock | -18,428 | $16.26 | $300k | 97,994 | Sep 3, 2025 |
| Jan 15, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +95,500 | $0.00 | $0 | 95,500 | Jan 17, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.